Macular translocation - A therapeutic approach for neovascular macular degeneration in the era of anti-VEGF therapy?;Makulatranslokation - Eine Therapie der neovaskuläreMakuladegeneration im Zeitalter derAnti-VEGF-Therapie?

Klinische Monatsblatter fur Augenheilkunde

Volumn 226, Issue 1, 2009, Pages 31-37

  Ziemssen, F ^a   Gelisken, F ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Age related macular degeneration; Anti VEGF; Bevacizumab; Macular translocation; Pegaptanib; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN RECEPTOR;

BINOCULAR VISION; HUMAN; INTRAOCULAR HEMORRHAGE; OUTCOME ASSESSMENT; PATIENT SELECTION; PHOTODYNAMICS; PIGMENT EPITHELIUM; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA TRANSLOCATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL DISORDER; DRUG ANTAGONISM; EYE SURGERY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA DEGENERATION; RETINA MACULA LUTEA; RETINA NEOVASCULARIZATION;

HUMANS; MACULA LUTEA; MACULAR DEGENERATION; OPHTHALMOLOGIC SURGICAL PROCEDURES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINAL NEOVASCULARIZATION;

EID: 64349108518     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027763     Document Type: Review

References (54)

1. Brown D M., Kaiser P K., Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 1432-1444
2. Michels S, Rosenfeld P J. Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis. Klin Monatsbl Augenheilkd 2005 222 480-484
3. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993 111 1200-1209
4. Treatment in Photodynamic Therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999 117 1329-1345
5. Verteporphin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001 131 541-560
6. Potter M J., Szabo S M. Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. Br J Ophthalmol 2007 91 753-756
7. Bressler N M., Bressler S B., Hawkins B S. et al. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1. Am J Ophthalmol 2000 130 387-407
8. Eckardt C, Eckardt U, Conrad H G. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999 237 313-325
9. Machemer R. Macular translocation. Am J Ophthalmol 1998 125 698-700
10. Gelisken F, Karim-Zoda K, Grisanti S et al. Macular translocation with 360 degrees retinotomy for retinal pigment epithelial tear. Graefes Arch Clin Exp Ophthalmol 2005 243 619-621
11. Freedman S F., Holgado S, Enyedi L B. et al. Management of ocular torsion and diplopia after macular translocation for age-related macular degeneration: prospective clinical study. Am J Ophthalmol 2003 136 640-648
12. Klainguti G, Nguyen C. Surgical management of monocular torsion and head tilt after macular translocation. Klin Monatsbl Augenheilkd 2005 222 222-225
13. Sato M, Terasaki H, Ogino N et al. Strabological findings after macular translocation surgery with 360 degrees retinotomy. Invest Ophthalmol Vis Sci 2003 44 1939-1944
14. Makulakomission. Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 2007 224 559-566
15. Novartis Pharma GmbH. Fachinformation Lucentis®. Rote Liste GmbH 2007
16. Brown D M., Kaiser P K., Michels M et al. Supplementary Appendix. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 S1-S15
17. Rosenfeld P J., Brown D M., Heier J S. et al. Supplementary Appendix. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 355 S1-S17
18. Krebs I, Ansari-Shahrezaei S, Goll A et al. Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol 2008 246 811-815
19. Heimes B, Lommatzsch A, Zeimer M et al. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 2008 246 1229-1234
20. Brantley M A., Fang A M., King J M. et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007 114 2168-2173
21. Gelisken F Jr, Voelker M, Schwabe R et al. Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 2007 245 1085-1095
22. Ziemssen F, Lüke M, Bartz-Schmidt K U. et al. Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation). Graefes Arch Clin Exp Ophthalmol 2008 246 653-659
23. Cahill M T., Stinnett S S., Banks A D. et al. Quality of life after macular translocation with 360 degrees peripheral retinectomy for age-related macular degeneration. Ophthalmology 2005 112 144-151
24. Luke M, Ziemssen F, Bartz-Schmidt K U. et al. Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration a report of 1 year results. Graefes Arch Clin Exp Ophthalmol 2007 245 1831-1836
25. Luke M, Ziemssen F, Bartz-Schmidt K U. et al. Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration a report of 1 year results. Graefes Arch Clin Exp Ophthalmol 2007 245 1831-1836
26. Lanzetta P, ANCHOR and PIER study group. Ranibizumab and patient-reported outcomes: VFQ-25 data from the ANCHOR and PIER trials in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008 49 E-5571
27. Nguyen N X., Besch D, Bartz-Schmidt K et al. Reading performance with low-vision aids and vision-related quality of life after macular translocation surgery in patients with age-related macular degeneration. Acta Ophthalmol Scand 2007 85 877-882
28. Falkner C I., Leitich H, Frommlet F et al. The end of submacular surgery for age-related macular degeneration? A meta-analysis. Graefes Arch Clin Exp Ophthalmol 2007 245 490-501
29. Lux A, Llacer H, Heussen F M. et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007 91 1318-1322
30. Suesskind D, Voelker M, Bartz-Schmidt K U. et al. Full macular translocation following photodynamic therapy in neovascular age-related macular degeneration. Eye 2007 22 834-837
31. Rosenfeld P J., Shapiro H, Tuomi L et al. Lesion characteristics in Ranibizumab treated patients with a visual acuity gain or loss in the MARINA and ANCHOR trials for wet age-related macular degeneration. Invest Ophthalmol Vis Sci 2008 49 E-329
32. Casswell A G., Kohen D, Bird A C. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 1985 69 397-403
33. Gelisken F, Inhoffen W, Partsch M et al. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 2001 131 518-520
34. Hoskin A, Bird A C., Sehmi K. Tears of detached retinal pigment epithelium. Br J Ophthalmol 1981 65 417-422
35. Chan C K., Meyer C H., Gross J G. et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007 27 541-551
36. Gelisken F, Ziemssen F, Voelker M et al. Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye 2008 E-Pub
37. Amselem L, Pulido J S., Diaz-Llopis M et al. Retinal pigment epithelial tear following ranibizumab use. Eye 2007 21 846-847
38. Dhalla M S., Blinder K J., Tewari A et al. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 2006 141 752-754
39. Leitritz M, Gelisken F, Inhoffen W et al. Can the risk of retinal pigment epithelium tears after bevacizumab treatment be predicted? An optical coherence tomography study. Eye 2008 E-Pub
40. Lüke M, Januschowski K, Warga M et al. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 2007 91 1077-1082
41. Meyer C H., Scholl H P., Eter N et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 2008 E-Pub
42. Stifter E, Michels S, Prager F et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007 144 886-892
43. Scupola A, Coscas G, Soubrane G et al. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 1999 213 97-102
44. Schmidt J C., Meyer C H., Horle S. Massive subretinal hemorrhages. A challenge for vitreous body surgeons. Ophthalmologe 2004 101 584-588
45. Bhisitkul R B., Winn B J., Lee O T. et al. Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage. Invest Ophthalmol Vis Sci 2008 E-Pub
46. Mruthyunjaya P, Stinnett S S., Toth C A. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology 2004 111 1715-1724
47. Ninomiya Y, Lewis J M., Hasegawa T et al. Retinotomy and foveal translocation for surgical management of subfoveal choroidal neovascular membranes. Am J Ophthalmol 1996 122 613-621
48. Algvere P, Bill A. Effects of vitrectomy and phakectomy on the drainage of the vitreous compartment. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1981 216 253-260
49. Aisenbrey S, Bartz-Schmidt K U., Walter P et al. Long-term follow-up of macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 2007 125 1367-1372
50. Neugebauer A, Fricke J. Sensory problems after macular translocation. Ophthalmologe 2002 99 156-159
51. Yang Y, ANCHOR study group. Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3 mg and 0.5 mg with verteporphin therapy of predominantly classic CNV lesions secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2008 48 E-4545
52. Wu L, Martinez-Castellanos M A., Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008 246 81-87
53. Shima C, Sakaguchi H, Gomi F et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2008 86 372-376
54. McGimpsey S J., Gillies M C. Treatment of macular degeneration - controversy and hope. Br J Ophthalmol 2008 92 436-437